GBF achieved strong financial performance in 2024, with revenue up 12%, EBITDA margin improving from 4.3% to 5.2%, and free cash flow increasing by 55% to €189 million.
The company provided a positive outlook for 2025, projecting revenue between €5.1 billion and €5.7 billion, EBITDA margin of 5.2% to 5.8%, and cash flow of €210 million to €270 million.
Key growth drivers include stable demand in volatile markets, strong performance in Pharma, Biopharma, and energy sectors, and successful contract renewals in Europe and the Middle East.
GBF emphasized sustainability efforts, including reporting on Scope 3 emissions for the first time and achieving its learning and development spending target of over 0.5% of revenue.
The company plans to announce new midterm targets up to 2030 during its Capital Markets Day on December 2, 2025, aiming for a 6%-7% EBITDA margin and more than 80% cash conversion in the midterm.